¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Fanconi Anemia Complementation Group F Protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • protein error
    ´Ü¹é¿ÀÂ÷(Ó±ÛÜè¦ó¬).
  • protein extract
    ´Ü¹éÁúÃßÃâ¹°.
  • protein granule
    ´Ü¹éÁú°ú¸³
  • protein index
    ´Ü¹éÁö¼ö(Ó±ÛÜò¦â¦)
  • protein kinase
    ´Ü¹éÁú Ä«À̳×ÀÌÁî
  • protein kinase c
    ´Ü¹éÄ«À̳×À̽º(´Ü¹éŰ³ªÁ¦)C(Ó±ÛÜ¡­)
  • protein losing enteropathy
    ´Ü¹é»ó½Ç¼º À庴Áõ(Ó±ÛÜßÃã÷àõíóÜ»ñø).
  • protein losing enteropathy
    ´Ü¹é»ó½Ç¼º À庴Áõ(Ó±ÛÜßÃã÷àõ íóÜ»ñø)
  • protein losing gastroenteropathy
    ´Ü¹é»ó½Ç¼º À§ÀåÁõ(¡­êÖ ñø).
  • protein losing gastroenteropathy
    ´Ü¹é»ó½Ç¼º À§ÀåÁõ(Ó±ÛÜßÃã÷àõ êÖíóñø)
  • protein malnutrition
    ´Ü¹éÁú¿µ¾çÀå¾Ö(Ó±ÛÜòõç½å×î¡äô).
  • protein malnutrition
    ´Ü¹éÁú¿µ¾çÀå¾Ö(Ó±ÛÜòõç½å×î¡äô)
  • protein metabolism
    ´Ü¹é(Áú)´ë»ç.
  • protein milk
    (°í)´Ü¹éÀ¯(ÍÔÓ±ÛÜêá).
  • protein quotient
    ´Ü¹éÁö¼ö(ËÀËÑ̤Ëà).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • protein-bound iodine
    ´Ü¹éÁú°áÇÕ(Ó±ÛÜòõÌ¿ùê) ¿äµå
  • protein C
    ´Ü¹éÁú(Ó±ÛÜòõ) C
  • protein-calorie malnutrition
    ´Ü¹éÁú(Ó±ÛÜòõ)-Ä®·Î¸® ¿µ¾ç½ÇÁ¶(ç½å×ã÷ðà)
  • protein coat
    ´Ü¹éÁú(Ó±ÛÜòõ) ÄÚÆ®
  • protein conformation
    ´Ü¹éÁú(Ó±ÛÜòõ) ÀÔüÇüÅÂ(Ø¡ô÷û¡÷¾)
  • protein domain
    ´Ü¹éÁú ¿µ¿ª(Ó±ÛÜòõÖÅæ´)
  • protein efficiency ratio
    ´Ü¹éÁú(Ó±ÛÜòõ) È¿À²ºñ(üù×ËÝï)
  • protein efficiency ratio method
    ´Ü¹éÁú(Ó±ÛÜòõ) È¿À²ºñ¹ý(üù×ËÝïÛö)
  • protein engineering
    ´Ü¹éÁú °ø¹ý(Ó±ÛÜòõÍïÛö)
  • protein error
    ´Ü¹éÁú ¿ÀÂ÷(Ó±ÛÜòõè¦ó¬)
  • protein evolution
    ´Ü¹éÁú ÁøÈ­(Ó±ÛÜòõòäûù)
  • protein export
    ´Ü¹éÁú À¯Ãâ(Ó±ÛÜòõ×µõó)
  • protein factor
    ´Ü¹éÁú ÀÎÀÚ(Ó±ÛÜòõì×í­)
  • protein folding
    ´Ü¹éÁú(Ó±ÛÜòõ) Á¢±â
  • protein fractionation
    ´Ü¹éÁú ºÐȹȭ(Ó±ÛÜòõÝÂüñûù)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
MAA macroaggregated albumin; Medical Assistance for the Aged; melanoma-associated antigen; moderate apla...
MAHA microangiopathic hemolytic anemia
MHA major histocompatibility antigen; May-Hegglin anomaly; Mental Health Association; methemalbumin; mic...
PASA para-aminosalicylic acid; primary acquired sideroblastic anemia; proximal articular set angle
PDA patent ductus arteriosus; personal digital assistant; posterior descending artery; pulmonary disease...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
GOG Gynecologic Oncology Group
HGSHS:A Harvard Group Scale of Hypnotic Susceptibility, Form A
HMG High Mobility Group
HMGI High Mobility Group I
HMG I/Y High Mobility Group I/Y
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
cellular retinoic acid binding protein <protein> A cytoplasmic fatty acid binding protein that acts as an initial receptor for the putative morphogen, retinoic acid.
(18 Nov 1997)
glucose related protein <protein> One of the stress related proteins: identical to endoplasmin.
(18 Nov 1997)
rep protein <protein> A protein that triggers a plasmid's replication.
An acronym for Repetitive Extragenic Palindromicprotein, this protein is an enzyme produced by a mutant strain of E. Coli that unwinds the DNA helix.
(09 Oct 1997)
repressor protein <molecular biology> A protein that binds to an operator of a gene preventing the transcription of the gene. The binding affinity of repressors for the operator may be affected by other molecules. Inducers bind to repressors and decrease their binding to the operator, while co repressors increase the binding. The paradigm of repressor proteins is the lactose repressor protein that acts on the lac operon and for which the inducers are _ galactosides such as lactose, it is a polypeptide of 360 amino acids that is active as a tetramer. Other examples are the lambda repressor protein of lambda bacteriophage that prevents the transcription of the genes required for the lytic cycle leading to lysogeny and the cro protein, also of lambda, which represses the transcription of the lambda repressor protein establishing the lytic cycle. Both of these are active as dimers and have a common structural feature the helix turn helix motif that is thought to bind to DNA with the helices fitting into adjacent major grooves.
(18 Nov 1997)
VLA protein <protein> VLA 1 and VLA 2 were originally defined as antigens appearing on the surfaces of T lymphocytes 2-4 weeks after in vitro activation, they are now know to be part of the _ integrin family. Additional members of the subset are now known (VLA 3, VLA 4, VLA 5 and VLA 6), the _ subunits all being identical. Some of the VLA proteins are receptors for collagen, laminin or fibronectin and many are now known to be expressed on cells other than leucocytes.
(18 Nov 1997)
pelle-like protein kinase <enzyme> Mplk - mouse pelle-like kinase; mammalian homolog of drosophila pelle protein; expression is developmentally regulated and is greatest in liver; genbank l08476
Registry number: EC 2.7.10.-
Synonym: mplk (protein)
(26 Jun 1999)
ceramide-activated protein kinase <enzyme> Mw 97 kD; stimulation of kinase takes place during sphingomyelin pathway; has membrane-bound activity capable of phosphorylating a peptide derived from the sequence surrounding thr(699) of the epidermal growth factor receptor; has role in signal transduction for tumour necrosis factor
Registry number: EC 2.7.10.-
Synonym: cap kinase
(26 Jun 1999)
ceramide-activated protein phosphatase <enzyme> Belongs to the heterotrimeric subfamily of the pp2a group of serine-threonine protein phosphatases; involved in ceramide-mediated signal transduction; inhibited by okadaic acid
Registry number: EC 3.1.3.-
Synonym: ceramide-stimulated phosphatase, capp (enzyme)
(26 Jun 1999)
Vps15 protein kinase <enzyme> Functions with vps34p as a membrane-associated complex which facilitates the delivery of proteins into the vacuole in yeast; amino acid sequence has been determined
Registry number: EC 2.7.10.-
Synonym: vps15 gene product, vps15p
(26 Jun 1999)
retinoblastoma protein <molecular biology, protein> Product of the retinoblastoma tumour suppressor gene.
It is a nuclear phosphoprotein hypothesised to normally act as an inhibitor of cell proliferation. Rb protein is absent in retinoblastoma cell lines. It also has been shown to form complexes with the adenovirus e1a protein, the sv40 t antigen, and the human papilloma virus e7 protein.
(03 Jul 1999)
retinol-binding protein <molecular biology> Proteins which bind with retinol.
The retinol-binding protein found in plasma has an alpha-1 mobility on electrophoresis and a molecular weight of 21,000-22,000. The protein has one binding site for retinol and is responsible for the transport of vitamin A.
The retinol- protein complex (molecular weight 80,000 to 90,000) circulates in plasma in the form of a protein-protein complex with prealbumin. The retinol-binding protein found in tissue has a molecular weight of 14,000 and carries retinol as a non-covalently-bound ligand.
(03 Jul 1999)
PEP protein tyrosine phosphatase <enzyme> Pest - pro, glu, ser and thr; an intracellular ptpase expressed primarily by cells of haematopoietic origin; involved in regulating nuclear tyrosine phosphorylation; amino acid sequence has been determined
Registry number: EC 3.1.3.-
Synonym: pep ptpase, pest-enriched phosphatase, ptp-pest
(26 Jun 1999)
membrane protein <protein> A protein with regions permanently attached to a membrane (peripheral membrane protein) or inserted into a membrane integral membrane protein). Insertion into a membrane implies hydrophobic domains in the protein. All transport proteins are integral membrane proteins.
(18 Nov 1997)
channel protein <chemistry, physiology> A protein that facilitates the diffusion of molecules/ions across lipid membranes by forming a hydrophilic pore. most frequently multimeric with the pore formed by subunit interactions.
(18 Nov 1997)
G-protein <cell biology, molecular biology> Intracellular membrane-associated proteins activated by several (e.g., beta adrenergic) receptors.
They serve as second messengers or transducers of the receptor-initiated response to intracellular elements such as enzymes to initiate an effect. They are also mediators of activated cell-surface receptors and their enzymes or of ion channels.
They are responsible for activating a chain of events that alters the concentration of intracellular signaling molecules such as cyclic AMP and calcium. In turn, these intracellular messengers alter the behaviour of other target proteins within the cell.
These proteins have a high affinity for guanine nucleotides and hence are named "G" proteins.
Synonym: G-protein, GTP-binding proteins.
(12 Jul 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á